Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | Resonance Health Ltd (RHT.ASX) |
|---|---|
| Release Time | 30 Jan 2026, 9:55 a.m. |
| Price Sensitive | Yes |
Resonance Health reports quarterly progress
- Receipts from customers of $2.9M with positive net cashflow from operations of $0.1M
- Unaudited revenue of $8.0M for 1HFY26 with margins currently tracking higher than anticipated
- New Non-Invasive Liver Fibrosis medical device proof-of-concept-trial progressed and nearing completion of subject enrolment
Resonance Health made significant progress in each of its three focus areas: Clinical Trial Management CRO Services (Resonance Clinical), Software-as-a-Medical Device Image Analysis Services (SaMD), and Clinical Trial Site Services (TrialsWest). Resonance Clinical finalised the clinical study report for a major pharma clinical trial and progressed another $13.8M trial, with 48 patients now recruited out of a targeted 60. The TrialsWest business continues to expand, with the Osborne Park clinic exceeding expectations and the recently opened Mandurah clinic approaching breakeven run-rate ahead of schedule. The SaMD business secured new multi-year contracts and extensions with global pharma companies, with the total forward orders and bid pipeline now exceeding $10M. The company also completed testing and validation of its new 'Bridge' technology, which automates and simplifies customer interaction, with first implementation expected in Q3 FY26. Additionally, the company made progress in its 'Non-Invasive MRI Liver Fibrosis' SaMD extended proof-of-concept trial, with enrolment of the target participants now materially complete. The company generated unaudited revenue of $8.0M for 1HFY26 with expected margins higher than anticipated, and closed the quarter with $2.7M in cash and debt.
The company generated unaudited revenue of $8.0M for 1HFY26 with expected margins higher than anticipated.
The company continues to execute its strategy of rapid growth in its three businesses focus areas, underwritten by continued strong business development across the group, including the record bid pipeline in the SaMD business, strong growth in the TrialsWest clinics network, and continued solid execution of the Resonance Clinical CRO service delivery contracts.